Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ARTIVION, INC.CRY · Entity 4767 | VP, Clinical Research | March 12, 2021 | March 15, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ARTIVION, INC.
Report date March 12, 2021 · Filed March 15, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 153,203 |
Ending reported balance
After 2021-03-12 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2021-03-12 · Tax withholding · Disposed 1,160 · Balance 153,436 F1: Represent shares of restricted stock that were withheld for taxes on the grant vest date. Row 2 · 2021-03-12 · Tax withholding · Disposed 233 · Balance 153,203 F2: These shares were withheld upon the vesting of performance stock units to pay tax withholding obligations. |
Filing footnotes · ownership attribution and instrument terms
F1: Represent shares of restricted stock that were withheld for taxes on the grant vest date.
F2: These shares were withheld upon the vesting of performance stock units to pay tax withholding obligations.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 12, 2021 Filed Mar 15, 2021 20:19 UTC | ARTIVION, INC. CRY · Entity 4767 | Tax withholdingCommon Stock | 233 | $25.05 | $5,836.65 |
DisclosureSEC source: 0000784199-21-000089 · certent-form4.xml · nonDerivative · entry 2 Capps Scott B · CIK 0001409753 · VP, Clinical Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 153,203 F2 · shares: These shares were withheld upon the vesting of performance stock units to pay tax withholding obligations. Read SEC document |
| March 12, 2021 Filed Mar 15, 2021 20:19 UTC | ARTIVION, INC. CRY · Entity 4767 | Tax withholdingCommon Stock | 1,160 | $25.05 | $29,058.00 |
DisclosureSEC source: 0000784199-21-000089 · certent-form4.xml · nonDerivative · entry 1 Capps Scott B · CIK 0001409753 · VP, Clinical Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 153,436 F1 · shares: Represent shares of restricted stock that were withheld for taxes on the grant vest date. Read SEC document |
| March 05, 2021 Filed Mar 10, 2021 12:28 UTC | ARTIVION, INC. CRY · Entity 4767 | Tax withholdingCommon Stock | 205 | $24.44 | $5,010.20 |
DisclosureSEC source: 0000784199-21-000066 · certent-form4.xml · nonDerivative · entry 1 Capps Scott B · CIK 0001409753 · VP, Clinical Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,596 F1 · shares: These shares were withheld upon the vesting of performance stock units to pay tax withholding obligations. Read SEC document |
| February 23, 2021 Filed Feb 25, 2021 22:42 UTC | ARTIVION, INC. CRY · Entity 4767 | Tax withholdingCommon Stock | 563 | $25.41 | $14,305.83 |
DisclosureSEC source: 0000784199-21-000041 · certent-form4.xml · nonDerivative · entry 2 Capps Scott B · CIK 0001409753 · VP, Clinical Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,801 F2 · shares: These shares were withheld upon the vesting of performance stock units to pay tax withholding obligations. Read SEC document |
| February 23, 2021 Filed Feb 25, 2021 22:42 UTC | ARTIVION, INC. CRY · Entity 4767 | GrantCommon Stock | 3,176 | $0.00 | $0.00 |
DisclosureSEC source: 0000784199-21-000041 · certent-form4.xml · nonDerivative · entry 1 Capps Scott B · CIK 0001409753 · VP, Clinical Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,364 F1 · shares: Represents performance stock units granted on Feb 19, 2020 and repriced on Feb 8, 2021. Fifty percent (50%) were issued on Feb 23, 2021. The remaining shares earned in connection with the Feb 2020 grant will be eligible to vest and be issued as follows: 25% on 02/19/2022, and 25% on 02/19/2023, assuming continued employment on the relevant vesting date. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 21:15 UTC | ARTIVION, INC. CRY · Entity 4767 | GrantStock Options (Right to Buy) · Derivative | 10,016 | $0.00 Strike: $24.90 | $0.00 |
DisclosureSEC source: 0000784199-21-000017 · certent-form4.xml · derivative · entry 2 Capps Scott B · CIK 0001409753 · VP, Clinical Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,016 Underlying: Common Stock · 10,016 shares Expires 2028-02-17 F2 · derivative.exercise_date: Stock option vests 33 1/3% per year beginning on the first anniversary of the grant date. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 21:15 UTC | ARTIVION, INC. CRY · Entity 4767 | GrantCommon Stock | 3,548 | $0.00 | $0.00 |
DisclosureSEC source: 0000784199-21-000017 · certent-form4.xml · nonDerivative · entry 1 Capps Scott B · CIK 0001409753 · VP, Clinical Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,188 F1 · shares: Represents shares of restricted stock that vest on the third anniversary of the grant date if the reporting person remains in the continuous employ of the Company. Read SEC document |
| December 15, 2020 Filed Dec 16, 2020 21:27 UTC | ARTIVION, INC. CRY · Entity 4767 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $9.97 Strike: $9.97 | $99,700.00 |
DisclosureSEC source: 0000784199-20-000224 · certent-form4.xml · derivative · entry 3 Capps Scott B · CIK 0001409753 · VP, Clinical Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2021-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Stock option vests 33 1/3% per year beginning on the first anniversary of the grant date. The first exercisable date was 2/26/2015 Read SEC document |
| December 15, 2020 Filed Dec 16, 2020 21:27 UTC | ARTIVION, INC. CRY · Entity 4767 | SaleCommon Stock | 8,366 | $21.34 | $178,553.03 |
DisclosureSEC source: 0000784199-20-000224 · certent-form4.xml · nonDerivative · entry 2 Capps Scott B · CIK 0001409753 · VP, Clinical Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,640 F1 · price: Reflects weighted average price. Range was from $21.25 to $21.45. The reporting person will provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price. Read SEC document |
| December 15, 2020 Filed Dec 16, 2020 21:27 UTC | ARTIVION, INC. CRY · Entity 4767 | Exercise / conversionCommon Stock | 10,000 | $9.97 | $99,700.00 |
DisclosureSEC source: 0000784199-20-000224 · certent-form4.xml · nonDerivative · entry 1 Capps Scott B · CIK 0001409753 · VP, Clinical Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,006 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 05, 2020 Filed May 7, 2020 21:22 UTC | ARTIVION, INC. CRY · Entity 4767 | GrantPhantom Stock · Derivative | 1,797 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000784199-20-000119 · certent-form4.xml · derivative · entry 1 Capps Scott B · CIK 0001409753 · VP, Clinical Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,006 Underlying: Phantom Stock · 1,797 shares Expires not disclosed F1 · derivative.exercise_price: Represents phantom stock that is the economic equivalent of one share of CRY common stock. This phantom stock will not convert to shares, but will be settled in cash on or about April 27, 2021. F1 · price: Represents phantom stock that is the economic equivalent of one share of CRY common stock. This phantom stock will not convert to shares, but will be settled in cash on or about April 27, 2021. F1 · derivative.exercise_date: Represents phantom stock that is the economic equivalent of one share of CRY common stock. This phantom stock will not convert to shares, but will be settled in cash on or about April 27, 2021. F1 · derivative.expiration_date: Represents phantom stock that is the economic equivalent of one share of CRY common stock. This phantom stock will not convert to shares, but will be settled in cash on or about April 27, 2021. Read SEC document |
| March 12, 2020 Filed Mar 16, 2020 11:38 UTC | ARTIVION, INC. CRY · Entity 4767 | Tax withholdingCommon Stock | 233 | $20.24 | $4,715.92 |
DisclosureSEC source: 0000784199-20-000074 · certent-form4.xml · nonDerivative · entry 2 Capps Scott B · CIK 0001409753 · VP, Clinical Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,006 F2 · shares: These shares were withheld upon the vesting of performance stock units to pay tax withholding obligations. Read SEC document |
| March 12, 2020 Filed Mar 16, 2020 11:38 UTC | ARTIVION, INC. CRY · Entity 4767 | GrantCommon Stock | 1,998 | $0.00 | $0.00 |
DisclosureSEC source: 0000784199-20-000074 · certent-form4.xml · nonDerivative · entry 1 Capps Scott B · CIK 0001409753 · VP, Clinical Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,239 F1 · balance_after: Balance reflects a share correction that was duplicated on 02.21.2020. Read SEC document |
| March 05, 2020 Filed Mar 9, 2020 20:07 UTC | ARTIVION, INC. CRY · Entity 4767 | Tax withholdingCommon Stock | 350 | $24.93 | $8,725.50 |
DisclosureSEC source: 0000784199-20-000055 · certent-form4.xml · nonDerivative · entry 2 Capps Scott B · CIK 0001409753 · VP, Clinical Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,237 F2 · shares: These shares were withheld upon the vesting of performance stock units to pay tax withholding obligations. Read SEC document |
| March 05, 2020 Filed Mar 9, 2020 20:07 UTC | ARTIVION, INC. CRY · Entity 4767 | GrantCommon Stock | 2,320 | $0.00 | $0.00 |
DisclosureSEC source: 0000784199-20-000055 · certent-form4.xml · nonDerivative · entry 1 Capps Scott B · CIK 0001409753 · VP, Clinical Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,587 F1 · shares: Represents performance stock units granted on March 5, 2019 and earned at approximately 82.5% of target based on 2019 adjusted EBITDA. Fifty percent (50%) were issued on March 5, 2020. The remaining shares earned in connection with the March 2019 grant will vest and be issued as follows: 25% on 03/05/2021, and 25% on 03/5/2022, assuming continued employment on the relevant vesting date. Read SEC document |
| February 21, 2020 Filed Feb 25, 2020 21:30 UTC | ARTIVION, INC. CRY · Entity 4767 | Tax withholdingCommon Stock | 292 | $26.20 | $7,650.40 |
DisclosureSEC source: 0000784199-20-000039 · certent-form4.xml · nonDerivative · entry 3 Capps Scott B · CIK 0001409753 · VP, Clinical Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,267 F3 · shares: These shares were withheld upon the vesting of performance stock units to pay tax withholding obligations. Read SEC document |
| February 21, 2020 Filed Feb 25, 2020 21:30 UTC | ARTIVION, INC. CRY · Entity 4767 | GrantCommon Stock | 1,998 | $0.00 | $0.00 |
DisclosureSEC source: 0000784199-20-000039 · certent-form4.xml · nonDerivative · entry 2 Capps Scott B · CIK 0001409753 · VP, Clinical Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,559 F2 · shares: Represents performance stock units granted on February 21, 2017 and earned at approximately 90% of target based on 2017 adjusted EBITDA. Fifty percent (50%) were issued on March 5, 2018. The remaining shares earned in connection with the February 2017 grant will vest and be issued as follows: 50% on 02/21/2019, and 50% on 02/21/2020, assuming continued employment on the relevant vesting date. Read SEC document |
| February 21, 2020 Filed Feb 25, 2020 21:30 UTC | ARTIVION, INC. CRY · Entity 4767 | Tax withholdingCommon Stock | 1,510 | $26.20 | $39,562.00 |
DisclosureSEC source: 0000784199-20-000039 · certent-form4.xml · nonDerivative · entry 1 Capps Scott B · CIK 0001409753 · VP, Clinical Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,561 F1 · shares: Represent shares of restricted stock that were withheld for taxes on the grant vest date. Read SEC document |
| February 19, 2020 Filed Feb 21, 2020 21:55 UTC | ARTIVION, INC. CRY · Entity 4767 | GrantStock Option(Right to Buy) · Derivative | 9,645 | $0.00 Strike: $26.24 | $0.00 |
DisclosureSEC source: 0000784199-20-000021 · certent-form4.xml · derivative · entry 2 Capps Scott B · CIK 0001409753 · VP, Clinical Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,645 Underlying: Common Stock · 9,645 shares Expires 2027-02-19 F2 · derivative.exercise_date: Stock option vests 33 1/3% per year beginning on the first anniversary of the grant date. Read SEC document |
| February 19, 2020 Filed Feb 21, 2020 21:55 UTC | ARTIVION, INC. CRY · Entity 4767 | GrantCommon Stock | 3,176 | $0.00 | $0.00 |
DisclosureSEC source: 0000784199-20-000021 · certent-form4.xml · nonDerivative · entry 1 Capps Scott B · CIK 0001409753 · VP, Clinical Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,071 F1 · shares: Represents shares of restricted stock that vest on the third anniversary of the grant date if the reporting person remains in the continuous employ of the Company. Read SEC document |
| November 26, 2019 Filed Nov 27, 2019 21:13 UTC | ARTIVION, INC. CRY · Entity 4767 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $6.12 Strike: $6.12 | $61,200.00 |
DisclosureSEC source: 0000784199-19-000166 · certent-form4.xml · derivative · entry 3 Capps Scott B · CIK 0001409753 · VP, Clinical Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2020-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Stock option vests 33 1/3% per year beginning on the first anniversary of the grant date. The first exercisable date was 2/15/2014 Read SEC document |
| November 26, 2019 Filed Nov 27, 2019 21:13 UTC | ARTIVION, INC. CRY · Entity 4767 | SaleCommon Stock | 7,184 | $24.93 | $179,107.90 |
DisclosureSEC source: 0000784199-19-000166 · certent-form4.xml · nonDerivative · entry 2 Capps Scott B · CIK 0001409753 · VP, Clinical Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,895 F1 · price: Reflects weighted average price. Range was from $24.93 to $24.99. The reporting person will provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price. Read SEC document |
| November 26, 2019 Filed Nov 27, 2019 21:13 UTC | ARTIVION, INC. CRY · Entity 4767 | Exercise / conversionCommon Stock | 10,000 | $6.12 | $61,200.00 |
DisclosureSEC source: 0000784199-19-000166 · certent-form4.xml · nonDerivative · entry 1 Capps Scott B · CIK 0001409753 · VP, Clinical Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,079 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 31, 2019 Filed Jun 3, 2019 20:31 UTC | ARTIVION, INC. CRY · Entity 4767 | SaleCommon Stock | 2,000 | $28.55 | $57,100.00 |
DisclosureSEC source: 0000784199-19-000131 · certent-form4.xml · nonDerivative · entry 1 Capps Scott B · CIK 0001409753 · VP, Clinical Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,079 F1 · price: Reflects weighted average price. Range was from $28.5 to $28.615. The reporting person will provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price. Read SEC document |
| March 14, 2019 Filed Mar 18, 2019 20:51 UTC | ARTIVION, INC. CRY · Entity 4767 | Tax withholdingCommon Stock | 466 | $28.92 | $13,476.72 |
DisclosureSEC source: 0000784199-19-000076 · certent-form4.xml · nonDerivative · entry 3 Capps Scott B · CIK 0001409753 · VP, Clinical Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,079 F3 · shares: These shares were withheld upon the vesting of performance stock units to pay tax withholding obligations. Read SEC document |
| March 14, 2019 Filed Mar 18, 2019 20:51 UTC | ARTIVION, INC. CRY · Entity 4767 | GrantCommon Stock | 3,092 | $0.00 | $0.00 |
DisclosureSEC source: 0000784199-19-000076 · certent-form4.xml · nonDerivative · entry 2 Capps Scott B · CIK 0001409753 · VP, Clinical Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,545 F2 · shares: Represents performance stock units granted on March 12, 2018 and earned at approximately 80% of target based on 2018 adjusted EBITDA. Fifty percent (50%) were issued on March 14, 2018. The remaining shares earned in connection with the March 2018 grant will vest and be issued as follows: 50% on 03/12/2020, and 50% on 03/12/2021, assuming continued employment on the relevant vesting date. Read SEC document |
| March 14, 2019 Filed Mar 18, 2019 20:51 UTC | ARTIVION, INC. CRY · Entity 4767 | Tax withholdingCommon Stock | 2 | $29.70 | $59.40 |
DisclosureSEC source: 0000784199-19-000076 · certent-form4.xml · nonDerivative · entry 1 Capps Scott B · CIK 0001409753 · VP, Clinical Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,453 F1 · shares: This is an adjustment to the shares withheld for taxes for the 3/1/2019 PSU Vesting. Read SEC document |
| March 05, 2019 Filed Mar 8, 2019 02:56 UTC | ARTIVION, INC. CRY · Entity 4767 | GrantStock Option (Right to Buy) · Derivative | 7,265 | $0.00 Strike: $29.62 | $0.00 |
DisclosureSEC source: 0000784199-19-000066 · certent-form4.xml · derivative · entry 2 Capps Scott B · CIK 0001409753 · VP, Clinical Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,265 Underlying: Common Stock · 7,265 shares Expires 2026-03-05 F2 · derivative.exercise_date: Stock option vests 33 1/3% per year beginning on the first anniversary of the grant date. Read SEC document |
| March 05, 2019 Filed Mar 8, 2019 02:56 UTC | ARTIVION, INC. CRY · Entity 4767 | GrantCommon Stock | 2,813 | $0.00 | $0.00 |
DisclosureSEC source: 0000784199-19-000066 · certent-form4.xml · nonDerivative · entry 1 Capps Scott B · CIK 0001409753 · VP, Clinical Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,455 F1 · shares: Represents share of restricted stock that vest on the third anniversary of the grant date if the reporting person remains in the continuous employ of the Company. Read SEC document |
| March 01, 2019 Filed Mar 4, 2019 13:03 UTC | ARTIVION, INC. CRY · Entity 4767 | Tax withholdingCommon Stock | 1,087 | $29.70 | $32,283.90 |
DisclosureSEC source: 0000784199-19-000030 · certent-form4.xml · nonDerivative · entry 1 Capps Scott B · CIK 0001409753 · VP, Clinical Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,642 F1 · shares: These shares were withheld upon the vesting of performance stock units to pay tax withholding obligations. Read SEC document |
| February 19, 2019 Filed Feb 21, 2019 22:28 UTC | ARTIVION, INC. CRY · Entity 4767 | Tax withholdingCommon Stock | 2,358 | $28.84 | $68,004.72 |
DisclosureSEC source: 0000784199-19-000018 · certent-form4.xml · nonDerivative · entry 1 Capps Scott B · CIK 0001409753 · VP, Clinical Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,729 F1 · shares: Represent shares of restricted stock that were withheld for taxes on the grant vest date. Read SEC document |
| August 30, 2018 Filed Sep 4, 2018 22:59 UTC | ARTIVION, INC. CRY · Entity 4767 | Exercise / conversionStock Option (Right to Buy) · Derivative | 8,332 | $5.67 Strike: $5.67 | $47,242.44 |
DisclosureSEC source: 0000784199-18-000183 · certent-form4.xml · derivative · entry 3 Capps Scott B · CIK 0001409753 · VP, Clinical Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,332 shares Expires 2019-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Stock option vests 33 1/3% per year beginning on the first anniversary of the grant date. The first exercisable date was 2/18/2013 Read SEC document |
| August 30, 2018 Filed Sep 4, 2018 22:59 UTC | ARTIVION, INC. CRY · Entity 4767 | SaleCommon Stock | 6,332 | $34.10 | $215,921.20 |
DisclosureSEC source: 0000784199-18-000183 · certent-form4.xml · nonDerivative · entry 2 Capps Scott B · CIK 0001409753 · VP, Clinical Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,087 F1 · price: Reflects weighted average price. Range was from $34.10 to $34.15. The reporting person will provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price. Read SEC document |
| August 30, 2018 Filed Sep 4, 2018 22:59 UTC | ARTIVION, INC. CRY · Entity 4767 | Exercise / conversionCommon Stock | 8,332 | $5.67 | $47,242.44 |
DisclosureSEC source: 0000784199-18-000183 · certent-form4.xml · nonDerivative · entry 1 Capps Scott B · CIK 0001409753 · VP, Clinical Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,419 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 12, 2018 Filed Mar 14, 2018 23:47 UTC | ARTIVION, INC. CRY · Entity 4767 | GrantStock Option (Right to Buy) · Derivative | 9,944 | $0.00 Strike: $21.55 | $0.00 |
DisclosureSEC source: 0000784199-18-000063 · certent-form4.xml · derivative · entry 2 Capps Scott B · CIK 0001409753 · VP, Clinical Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,944 Underlying: Common Stock · 9,944 shares Expires 2025-03-12 Read SEC document |
| March 12, 2018 Filed Mar 14, 2018 23:47 UTC | ARTIVION, INC. CRY · Entity 4767 | GrantCommon Stock | 3,867 | $0.00 | $0.00 |
DisclosureSEC source: 0000784199-18-000063 · certent-form4.xml · nonDerivative · entry 1 Capps Scott B · CIK 0001409753 · VP, Clinical Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,087 F1 · shares: Represents share of restricted stock that vest on the third anniversary of the grant date if the reporting person remains in the continuous employ of the Company. Read SEC document |
| March 05, 2018 Filed Mar 7, 2018 22:19 UTC | ARTIVION, INC. CRY · Entity 4767 | Tax withholdingCommon Stock | 607 | $19.15 | $11,624.05 |
DisclosureSEC source: 0000784199-18-000038 · certent-form4.xml · nonDerivative · entry 2 Capps Scott B · CIK 0001409753 · VP, Clinical Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,220 F2 · shares: These shares were withheld upon the vesting of performance stock units to pay tax withholding obligations. Read SEC document |
| March 05, 2018 Filed Mar 7, 2018 22:19 UTC | ARTIVION, INC. CRY · Entity 4767 | GrantCommon Stock | 4,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000784199-18-000038 · certent-form4.xml · nonDerivative · entry 1 Capps Scott B · CIK 0001409753 · VP, Clinical Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,827 F1 · shares: Represents performance stock units granted on February 21, 2017 and earned at approximately 90% of target based on 2017 adjusted EBITDA. Fifty percent (50%) were issued on March 5, 2018. The remaining shares earned in connection with the February 2017 grant will vest and be issued as follows: 50% on 02/21/2019, and 50% on 02/21/2020, assuming continued employment on the relevant vesting date. Read SEC document |
| February 19, 2018 Filed Feb 22, 2018 00:44 UTC | ARTIVION, INC. CRY · Entity 4767 | Tax withholdingCommon Stock | 2,246 | $18.25 | $40,989.50 |
DisclosureSEC source: 0000784199-18-000030 · certent-form4.xml · nonDerivative · entry 1 Capps Scott B · CIK 0001409753 · VP, Clinical Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,827 F1 · shares: Represent shares of restricted stock that were withheld for taxes on the grant vest date. Read SEC document |
| February 19, 2018 Filed Feb 21, 2018 22:15 UTC | ARTIVION, INC. CRY · Entity 4767 | Tax withholdingCommon Stock | 795 | $18.25 | $14,508.75 |
DisclosureSEC source: 0000784199-18-000014 · certent-form4.xml · nonDerivative · entry 2 Capps Scott B · CIK 0001409753 · VP, Clinical Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,073 F1 · shares: These shares were withheld upon the vesting of performance stock units to pay tax withholding obligations. Read SEC document |
| February 19, 2018 Filed Feb 21, 2018 22:15 UTC | ARTIVION, INC. CRY · Entity 4767 | Tax withholdingCommon Stock | 726 | $18.25 | $13,249.50 |
DisclosureSEC source: 0000784199-18-000014 · certent-form4.xml · nonDerivative · entry 1 Capps Scott B · CIK 0001409753 · VP, Clinical Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,868 F1 · shares: These shares were withheld upon the vesting of performance stock units to pay tax withholding obligations. Read SEC document |
| February 13, 2018 Filed Feb 15, 2018 22:28 UTC | ARTIVION, INC. CRY · Entity 4767 | Exercise / conversionStock Options (Right to Buy) · Derivative | 31,333 | $17.10 Strike: $5.12 | $535,794.30 |
DisclosureSEC source: 0000784199-18-000012 · certent-form4.xml · derivative · entry 3 Capps Scott B · CIK 0001409753 · VP, Clinical Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 31,333 shares Expires 2018-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: Stock option vests 33 1/3% per year beginning on the first anniversary of the grant date. The first exercisable date was 2/23/2012 Read SEC document |
| February 13, 2018 Filed Feb 15, 2018 22:28 UTC | ARTIVION, INC. CRY · Entity 4767 | Exercise / conversionCommon Stock | 31,333 | $5.12 | $160,424.96 |
DisclosureSEC source: 0000784199-18-000012 · certent-form4.xml · nonDerivative · entry 2 Capps Scott B · CIK 0001409753 · VP, Clinical Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,594 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: Stock option vests 33 1/3% per year beginning on the first anniversary of the grant date. The first exercisable date was 2/23/2012 Read SEC document |
| February 13, 2018 Filed Feb 15, 2018 22:28 UTC | ARTIVION, INC. CRY · Entity 4767 | Tax withholdingCommon Stock | 9,381 | $17.10 | $160,415.10 |
DisclosureSEC source: 0000784199-18-000012 · certent-form4.xml · nonDerivative · entry 1 Capps Scott B · CIK 0001409753 · VP, Clinical Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,261 F1 · shares: Payment of exercise by delivering shares in accordance to Rule 16b-3. Read SEC document |
| February 26, 2017 Filed Feb 28, 2017 22:28 UTC | ARTIVION, INC. CRY · Entity 4767 | Tax withholdingCommon Stock | 417 | $17.25 | $7,193.25 |
DisclosureSEC source: 0000784199-17-000031 · certent-form4.xml · nonDerivative · entry 2 Capps Scott B · CIK 0001409753 · VP, Clinical Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,642 F2 · shares: These shares were withheld upon the vesting of performance stock units to pay tax withholding obligations. Read SEC document |
| February 26, 2017 Filed Feb 28, 2017 22:28 UTC | ARTIVION, INC. CRY · Entity 4767 | Tax withholdingCommon Stock | 3,335 | $17.25 | $57,528.75 |
DisclosureSEC source: 0000784199-17-000031 · certent-form4.xml · nonDerivative · entry 1 Capps Scott B · CIK 0001409753 · VP, Clinical Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,059 F1 · shares: These shares were withheld upon the vesting of restricted stock to pay tax withholding obligations. Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 14:10 UTC | ARTIVION, INC. CRY · Entity 4767 | Exercise / conversionStock Options (Right to Buy) · Derivative | 16,667 | $16.40 Strike: $7.01 | $273,360.47 |
DisclosureSEC source: 0000784199-17-000027 · certent-form4.xml · derivative · entry 3 Capps Scott B · CIK 0001409753 · VP, Clinical Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,667 shares Expires 2017-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 14:10 UTC | ARTIVION, INC. CRY · Entity 4767 | SaleCommon Stock | 11,083 | $16.40 | $181,775.61 |
DisclosureSEC source: 0000784199-17-000027 · certent-form4.xml · nonDerivative · entry 2 Capps Scott B · CIK 0001409753 · VP, Clinical Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,394 F2 · price: Reflects weighted average price. Range was $16.35 to $16.45 The reporting person will provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price. Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 14:10 UTC | ARTIVION, INC. CRY · Entity 4767 | Exercise / conversionCommon Stock | 16,667 | $7.01 | $116,835.67 |
DisclosureSEC source: 0000784199-17-000027 · certent-form4.xml · nonDerivative · entry 1 Capps Scott B · CIK 0001409753 · VP, Clinical Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,477 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Stock option vests 33 1/3% per year beginning on the first anniversary of the grant date. The first exercisable date was 2/22/2011 Read SEC document |
| February 21, 2017 Filed Feb 22, 2017 23:33 UTC | ARTIVION, INC. CRY · Entity 4767 | GrantCommon Stock | 4,444 | $0.00 | $0.00 |
DisclosureSEC source: 0000784199-17-000009 · certent-form4.xml · nonDerivative · entry 4 Capps Scott B · CIK 0001409753 · VP, Clinical Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,810 F3 · shares: Represents share of restricted stock that vest on the third anniversary of the grant date if the reporting person remains in the continuous employ of the Company. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.